AAAAAA
Results: 1-25/50
Authors:
KOMAKI R
MILAS L
RO JY
FUJII T
PERKINS P
ALLEN P
SIKES CR
MOUNTAIN CF
ORDONEZ NG
Citation: R. Komaki et al., PROGNOSTIC BIOMARKER STUDY IN PATHOLOGICALLY STAGED N1 NONSMALL CELL LUNG-CANCER, International journal of radiation oncology, biology, physics, 40(4), 1998, pp. 787-796
Authors:
GROS F
MAILLEFERT JF
MARTIN D
MILAS L
PIROTH C
TAVERNIER C
Citation: F. Gros et al., EPIDURAL HEMATOMA IN A WOMAN UNDER ANTIPL ATELET THERAPY, La Semaine des hopitaux de Paris, 74(3-4), 1998, pp. 86-89
Authors:
LI C
YU DF
NEWMAN RA
CABRAL F
STEPHENS LC
HUNTER N
MILAS L
WALLACE S
Citation: C. Li et al., COMPLETE REGRESSION OF WELL-ESTABLISHED TUMORS USING A NOVEL WATER-SOLUBLE POLY(L-GLUTAMIC ACID) PACLITAXEL CONJUGATE, Cancer research, 58(11), 1998, pp. 2404-2409
Authors:
MASON KA
HUNTER NR
MILAS M
ABBRUZZESE JL
MILAS L
Citation: Ka. Mason et al., DOCETAXEL ENHANCES TUMOR RADIORESPONSE IN-VIVO, Clinical cancer research, 3(12), 1997, pp. 2431-2438
Authors:
MILROSS CG
MASON KA
HUNTER NR
TERRY NHA
PATEL N
HARADA S
JIBU T
SEONG J
MILAS L
Citation: Cg. Milross et al., ENHANCED RADIORESPONSE OF PACLITAXEL-SENSITIVE AND PACLITAXEL-RESISTANT TUMORS IN-VIVO, European journal of cancer, 33(8), 1997, pp. 1299-1308
Authors:
SEONG J
MILROSS CG
HUNTER NR
SHIN HC
MILAS L
Citation: J. Seong et al., POTENTIATION OF ANTITUMOR EFFICACY OF PACLITAXEL BY RECOMBINANT TUMOR-NECROSIS-FACTOR-ALPHA, Anti-cancer drugs, 8(1), 1997, pp. 80-87
Authors:
MILAS L
Citation: L. Milas, INTERACTIONS OF RADIATION WITH NOVEL CHEMOTHERAPEUTIC-AGENTS - TAXANES AND NUCLEOSIDE ANALOGS, International journal of radiation oncology, biology, physics, 39(2), 1997, pp. 131-131
Authors:
SAITO Y
MILROSS CG
HITTELMAN WN
LI DH
JIBU T
PETERS LJ
MILAS L
Citation: Y. Saito et al., EFFECT OF RADIATION AND PACLITAXEL ON P53 EXPRESSION IN MURINE TUMORSSENSITIVE OR RESISTANT TO APOPTOSIS INDUCTION, International journal of radiation oncology, biology, physics, 38(3), 1997, pp. 623-631
Authors:
MILROSS CG
TUCKER SL
MASON KA
HUNTER NR
MILAS L
Citation: Cg. Milross et al., THE EFFECT OF TUMOR SIZE ON NECROSIS AND POLAROGRAPHICALLY MEASURED PO(2), Acta oncologica, 36(2), 1997, pp. 183-189
Authors:
LI C
YU DF
INOUE T
YANG DJ
TANSEY W
LIU CW
MILAS L
HUNTER NR
KIM EE
WALLACE S
Citation: C. Li et al., SYNTHESIS, BIODISTRIBUTION AND IMAGING PROPERTIES OF INDIUM-111-DTPA-PACLITAXEL IN MICE BEARING MAMMARY-TUMORS, The Journal of nuclear medicine, 38(7), 1997, pp. 1042-1047
Authors:
NOZUE M
LEE I
YUAN F
TEICHER BA
BRIZEL DM
DEWHIRST MW
MILROSS CG
MILAS L
SONG CW
THOMAS CD
GUICHARD M
EVANS SM
KOCH CJ
LORD EM
JAIN RK
SUIT HD
Citation: M. Nozue et al., INTERLABORATORY VARIATION IN OXYGEN-TENSION MEASUREMENT BY EPPENDORF HISTOGRAPH AND COMPARISON WITH HYPOXIC MARKER, Journal of surgical oncology, 66(1), 1997, pp. 30-38
Authors:
MILROSS CG
MASON KA
HUNTER NR
CHUNG WK
PETERS LJ
MILAS L
Citation: Cg. Milross et al., RELATIONSHIP OF MITOTIC ARREST AND APOPTOSIS TO ANTITUMOR EFFECT OF PACLITAXEL, Journal of the National Cancer Institute, 88(18), 1996, pp. 1308-1314
Authors:
INOUE T
YANG DJ
WALLACE S
CHERIF A
TANSEY W
KIM EE
HUNTER N
MILROSS CG
MILAS L
PODOLOFF DA
Citation: T. Inoue et al., EVALUATION OF [I-131] IODOERYTHRONITROIMIDAZOLE AS A PREDICTOR FOR THE RADIOSENSITIZING EFFECT, Anti-cancer drugs, 7(8), 1996, pp. 858-865
Authors:
LI C
YU DF
INOUE T
YANG DJ
MILAS L
HUNTER NR
KIM EE
WALLACE S
Citation: C. Li et al., SYNTHESIS AND EVALUATION OF WATER-SOLUBLE POLYETHYLENE GLYCOL-PACLITAXEL CONJUGATE AS A PACLITAXEL PRODRUG, Anti-cancer drugs, 7(6), 1996, pp. 642-648
Authors:
KOMAKI R
FUJII T
PERKINS P
RO JY
ALLEN PK
MASON KA
MOUNTAIN CF
MILAS L
Citation: R. Komaki et al., APOPTOSIS AND MITOSIS AS PROGNOSTIC FACTORS IN PATHOLOGICALLY STAGED N1 NONSMALL CELL LUNG-CANCER, International journal of radiation oncology, biology, physics, 36(3), 1996, pp. 601-605
Authors:
THAMES HD
RUIFROK ACC
MILAS L
HUNTER N
MASON KA
TERRY NHA
WHITE RA
Citation: Hd. Thames et al., ACCELERATED REPOPULATION DURING FRACTIONATED-IRRADIATION OF A MURINE OVARIAN-CARCINOMA - DOWN-REGULATION OF APOPTOSIS AS A POSSIBLE MECHANISM, International journal of radiation oncology, biology, physics, 35(5), 1996, pp. 951-962
Authors:
MILAS L
SAITO Y
HUNTER N
MILROSS CG
MASON KA
Citation: L. Milas et al., THERAPEUTIC POTENTIAL OF PACLITAXEL-RADIATION TREATMENT OF A MURINE OVARIAN-CARCINOMA, Radiotherapy and oncology, 40(2), 1996, pp. 163-170
Authors:
MEYN RE
STEPHENS LC
MILAS L
Citation: Re. Meyn et al., PROGRAMMED CELL-DEATH AND RADIORESISTANCE, Cancer metastasis reviews, 15(1), 1996, pp. 119-131
Authors:
YANG DJ
CHERIF A
ORIUCHI N
TANSEY W
KUANG LR
WALLACE S
KIM EE
MILAS L
PODOLOFF DA
Citation: Dj. Yang et al., DEVELOPMENT OF ACETYLACETONE-2-NITROIMIDAZOLE CONJUGATE AS A NEW IMAGING KIT FOR HYPOXIC TISSUES, The Journal of nuclear medicine, 37(5), 1996, pp. 277-277
Authors:
INOUE T
YANG DJ
MILAS L
WALLACE S
CHERIF A
TANSEY W
KIM EE
MILAS L
ENDO K
PODOLOFF DA
Citation: T. Inoue et al., EVALUATION OF [I-131] IODOERYTHRONITROIMIDAZOLE AS MARKER FOR TUMOR HYPOXIA AND PREDICTOR FOR RADIOSENSITIZING EFFECT, The Journal of nuclear medicine, 37(5), 1996, pp. 1133-1133
Authors:
LI C
INOUE T
YU DF
YANG DJ
TANSEY W
DIAZ M
MILAS L
HUNTER LR
LIM SS
PODOLLOF D
WALLACE S
Citation: C. Li et al., SYNTHESIS AND IN-VIVO EVALUATION OF IN-111 LABELED PACLITAXEL - IMPLICATIONS FOR TUMOR IMAGING, The Journal of nuclear medicine, 37(10), 1996, pp. 1804-1804
Authors:
KATAOKA Y
PERRIN J
HUNTER N
MILAS L
GRDINA DJ
Citation: Y. Kataoka et al., ANTIMUTAGENIC EFFECTS OF AMIFOSTINE - CLINICAL IMPLICATIONS, Seminars in oncology, 23(4), 1996, pp. 53-57
Authors:
GREGOIRE V
HUNTER NR
BROCK WA
HITTELMAN WN
PLUNKETT W
MILAS L
Citation: V. Gregoire et al., IMPROVEMENT IN THE THERAPEUTIC RATIO OF RADIOTHERAPY FOR A MURINE SARCOMA BY INDOMETHACIN PLUS FLUDARABINE, Radiation research, 146(5), 1996, pp. 548-553
Authors:
MILAS L
HANSON WR
Citation: L. Milas et Wr. Hanson, EICOSANOIDS AND RADIATION, European journal of cancer, 31A(10), 1995, pp. 1580-1585
Authors:
MEYN RE
STEPHENS LC
HUNTER NR
MILAS L
Citation: Re. Meyn et al., APOPTOSIS IN MURINE TUMORS TREATED WITH CHEMOTHERAPY AGENTS, Anti-cancer drugs, 6(3), 1995, pp. 443-450